Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
scientific article published on 10 February 2017
Author/s
author: Dana Horáková, Helmut Butzkueven, Tomáš Kalinčík, J William L Brown, Neil Scolding, Claire M Rice, Tjalf Ziemssen, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Eugenio Pucci, Vincent van Pesch, Mark Slee, Steve Vucic, Pamela A. McCombe, José Luis Sánchez Menoyo, Michael Hutchinson, Guillermo Izquierdo, Alexandre Prat, Pierre Duquette, Pierre Grammond, Michael Barnett, Patrizia Sola, Raed Alroughani, Raymond Hupperts, Eva Havrdová
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.